Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of APL-2 versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria and persistent anemia
2017-004268-36Phase 3Completed
- Sponsor
- Apellis Pharmaceuticals
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in paroxysmal nocturnal hemoglobinuria (PNH) comparing APL-2 with Soliris (2 arms). Primary endpoint: Change from baseline in hemoglobin level at Week 16. Started Jun 2018; status: completed.
02
Drugs
pegcetacoplaneculizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2017-004268-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004268-36.